171 related articles for article (PubMed ID: 23140577)
1. QSAR and docking studies of HCV NS3 serine protease inhibitors.
da Cunha EF; Matos KS; Ramalho TC
Med Chem; 2013 Sep; 9(6):774-805. PubMed ID: 23140577
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus NS3/4A protease.
Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
[TBL] [Abstract][Full Text] [Related]
3. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
6. A novel high throughput screening assay for HCV NS3 serine protease inhibitors.
Berdichevsky Y; Zemel R; Bachmatov L; Abramovich A; Koren R; Sathiyamoorthy P; Golan-Goldhirsh A; Tur-Kaspa R; Benhar I
J Virol Methods; 2003 Feb; 107(2):245-55. PubMed ID: 12505640
[TBL] [Abstract][Full Text] [Related]
7. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.
Takaya D; Yamashita A; Kamijo K; Gomi J; Ito M; Maekawa S; Enomoto N; Sakamoto N; Watanabe Y; Arai R; Umeyama H; Honma T; Matsumoto T; Yokoyama S
Bioorg Med Chem; 2011 Nov; 19(22):6892-905. PubMed ID: 21992802
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
[TBL] [Abstract][Full Text] [Related]
9. Resistance mutations against HCV protease inhibitors and antiviral drug design.
Shang L; Lin K; Yin Z
Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of NS3 protease inhibitors in HCV infection.
Goudreau N; Llinàs-Brunet M
Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.
Yeung KS; Meanwell NA; Qiu Z; Hernandez D; Zhang S; McPhee F; Weinheimer S; Clark JM; Janc JW
Bioorg Med Chem Lett; 2001 Sep; 11(17):2355-9. PubMed ID: 11527730
[TBL] [Abstract][Full Text] [Related]
12. Hexapeptide functionality of cellulose as NS3 protease inhibitors.
Ibrahim M; Saleh NA; Elshemey WM; Elsayed AA
Med Chem; 2012 Sep; 8(5):826-30. PubMed ID: 22741792
[TBL] [Abstract][Full Text] [Related]
13. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
Qin Z; Wang M; Yan A
Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
[TBL] [Abstract][Full Text] [Related]
14. Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.
Venkatraman S; Njoroge FG; Wu W; Girijavallabhan V; Prongay AJ; Butkiewicz N; Pichardo J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1628-32. PubMed ID: 16413182
[TBL] [Abstract][Full Text] [Related]
15. Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
Lasheen DS; Ismail MA; Abou El Ella DA; Ismail NS; Eid S; Vleck S; Glenn JS; Watts AG; Abouzid KA
Bioorg Med Chem; 2013 May; 21(10):2742-55. PubMed ID: 23583031
[TBL] [Abstract][Full Text] [Related]
16. Isosorbide-based peptidomimetics as inhibitors of hepatitis C virus serine protease.
Portela AC; Barros TG; Lima CHDS; Dias LRS; Azevedo PHRA; Dantas ASCL; Mohana-Borges R; Ventura GT; Pinheiro S; Muri EMF
Bioorg Med Chem Lett; 2017 Aug; 27(16):3661-3665. PubMed ID: 28729054
[TBL] [Abstract][Full Text] [Related]
17. Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate.
Milanole G; Andriessen F; Lemonnier G; Sebban M; Coadou G; Couve-Bonnaire S; Bonfanti JF; Jubault P; Pannecoucke X
Org Lett; 2015 Jun; 17(12):2968-71. PubMed ID: 26053226
[TBL] [Abstract][Full Text] [Related]
18. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
Das D; Pandya M
Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
[TBL] [Abstract][Full Text] [Related]
19. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase.
Attwood MR; Bennett JM; Campbell AD; Canning GG; Carr MG; Conway E; Dunsdon RM; Greening JR; Jones PS; Kay PB; Handa BK; Hurst DN; Jennings NS; Jordan S; Keech E; O'Brien MA; Overton HA; King-Underwood J; Raynham TM; Stenson KP; Wilkinson CS; Wilkinson TC; Wilson FX
Antivir Chem Chemother; 1999 Sep; 10(5):259-73. PubMed ID: 10574181
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
Li X; Liu Y; Zhang YK; Plattner JJ; Baker SJ; Bu W; Liu L; Zhou Y; Ding CZ; Zhang S; Kazmierski WM; Hamatake R; Duan M; Wright LL; Smith GK; Jarvest RL; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Wang A
Bioorg Med Chem Lett; 2012 Dec; 22(24):7351-6. PubMed ID: 23142614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
